Iscodil

Clopidogrel, the active ingredient in Iscodil, is an antiplatelet agent presented as an oral tablet for oral use. It inhibits platelet aggregation to help prevent atherothrombotic events in patients who have experienced myocardial infarction, ischemic stroke, transient ischemic attack, and associated cardiovascular complications under medical supervision.

GNH USA supplies Iscodil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery, regulatory compliance, and quality assurance across multiple regions.

Clopidogrel is indicated for several atherothrombotic conditions where platelet inhibition reduces clinical events. - Recent myocardial infarction: lowers risk of recurrent heart attacks and related vascular events. - Ischemic stroke or transient ischemic attack: decreases likelihood of subsequent stroke. - Peripheral arterial disease: provides secondary prevention of cardiovascular complications in established disease.

Clopidogrel may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate headache. - Nausea: occasional upset stomach. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe bleeding: gastrointestinal or intracranial hemorrhage. - Thrombocytopenia: marked reduction in platelet count. - Hypersensitivity reactions: including Stevens‑Johnson syndrome.

Before prescribing Clopidogrel, clinicians should consider several safety measures. - Assess bleeding risk: evaluate patient history of hemorrhage before initiating therapy. - Review concomitant anticoagulants: avoid combining with other potent antithrombotics unless clinically justified. - Monitor liver function: periodic testing recommended in patients with hepatic impairment. - Adjust for CYP2C19 polymorphism: consider alternative therapy in poor metabolizers. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Clopidogrel interacts with several drug classes that may alter its safety or efficacy.

Major Interactions (Avoid): - Oral anticoagulants (e.g., warfarin, DOACs): increased risk of major bleeding. - NSAIDs or aspirin: additive hemorrhagic effect. - Strong CYP2C19 inhibitors (e.g., omeprazole, fluconazole): reduced conversion to active metabolite, diminishing efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower plasma levels of clopidogrel. - Selective serotonin reuptake inhibitors (e.g., SSRIs): potential increase in bleeding tendency. - Glycoprotein IIb/IIIa inhibitors: additive antiplatelet activity.